Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Odetix (ODETA) best in mass data storage, going up!!! -- Ignore unavailable to you. Want to Upgrade?

To: ForYourEyesOnly who wrote (454)	10/27/1997 1:42:00 AM
From: Eduardo Canto	Read Replies (2) \| Respond to of 529

THC, Got one more year to finish Medical School. BIOX indeed looks attractive, should appreciate some on US Synvisc (crosslinked Hyaluronic Acid) launch by AHP if it builds enough momentum it might hit $50 by early '99. Hyalform revenues should be on the rise for the next few quarters as sales ramp up in Europe. If you are interested in the Hyaluronic Acid for Osteoarthritis market which ammounts to about $1B in US take a look at ANIK which has a natural, non crosslinked Hyaluronic Acid formulation which has finished ph III in US and is approved for sale in Europe where they are currently beginning to market the product. If their ph III data is good they could be selling the product in the US in '99. Compared to Biox mkt cap ~400M Anik is a bargain at ~56M with quarterly earnings of $0.05/shr on their ophthalmic product. Given that Biox is already approved in the US Anika is a more risky investment but with a greater upside potential. Good luck, Ed.